India News


PIB Headquarters


Posted On:
13 AUG 2021 6:53PM by PIB Delhi

  • Over 53 Cr. vaccine doses have been administered so far under Nationwide Vaccination Drive
  • Active cases constitute 1.20% of total cases; lowest since Mar 2020
  • India’s Active caseload currently 3,85,227
  • Highest ever Recovery Rate achieved; currently at 97.46%
  • 3,13,02,345 total recoveries across the country so far
  • 42,295 patients recovered during last 24 hours
  • India reports 40,120 new cases in last 24 hours
  • Weekly Positivity Rate remains below 5%, currently at 2.13%
  • Daily positivity rate at 2.04%; less than 3% for last 18 days
  • Testing capacity substantially ramped up – 48.94 crore tests conducted(Total)









COVID-19 Update

India’s Cumulative COVID-19 Vaccination Coverage crosses 53 Cr

More than 57 Lakh vaccine doses administered in last 24 hours

India achieves its highest ever Recovery Rate of 97.46%

40,120 Daily New Cases reported in last 24 hours

India’s Active Caseload (3,85,227)presently constitute 1.20% of total cases

Daily Positivity Rate (2.04%) less than 3% for last 18 days


India’s COVID-19 vaccination coverage has crossed 53 Crore today afternoon. Cumulatively, as per the provisional report till 7 am today,52,95,82,956 vaccine doses had been administered through 60,40,607 sessions. 57,31,574 vaccine doses were administered in the last 24 hours.

These include:


1st Dose


2nd Dose



1st Dose


2nd Dose


Age Group 18-44 years

1st Dose


2nd Dose


Age Group 45-59 years

1st Dose


2nd Dose


Over 60 years

1st Dose


2nd Dose





The new phase of universalization of COVID-19 vaccination has commenced from 21st June, 2021. The Union Government is committed to accelerating the pace and expanding the scope of COVID-19 vaccination throughout the country.

India’s recovery rate rises to 97.46%. This is the highest ever recovery rate achieved by India since the start of the pandemic.

Out of the people infected since the beginning of the pandemic, 3,13,02,345 people have already recovered from COVID-19 and 42,295 patients have recovered in the last 24 hours.


India has reported 40,120 daily new cases in the last 24 hours.

Less than 50,000 Daily New Cases have been reported since forty-sevenconsecutive days. This is a result of sustained and collaborative efforts by the Centre and the States/UTs.

India’s Active Caseload today stands at 3,85,227. Active cases now constitute only 1.20% of the country’s total Positive Cases, which isthe lowest since March 2020.

With substantially ramped up testing capacity across the country, a total of 19,70,495tests were conducted in the last 24 hours in the country. Cumulatively, India has conducted over 48.94 crore (48,94,70,779) tests so far.

While on one side testing capacity has been enhanced across the country, Weekly Positivity Rate currently stands at 2.13% and the Daily Positivity rate stands at 2.04% today. Daily Positivity rate has remained below 3% forlast 18 days and below 5% for 67 consecutive days now.



COVID-19 Vaccination Update

More than 55.01 Crore vaccine doses provided to States/UTs

More than 2.82 Crore balance and unutilized doses still available with States/UTs and private hospitals to be administered


As part of the nationwide vaccination drive, Government of India has been supporting the States and UTs by providing them COVID Vaccines free of cost. In the new phase of the universalization of the COVID19 vaccination drive, the Union Government will procure and supply (free of cost) 75% of the vaccines being produced by the vaccine manufacturers in the country to States and UTs.




(As on 13 August 2021)



















More than 55.01 crore (55,01,93,040) vaccine doses have been provided to States/UTs so far, through all sources and a further 59,16,920 doses are in the pipeline.

Of this, the total consumption including wastages is 52,59,93,669 doses (as per data available at 8 AM today).

More than 2.82 Cr (2,82,57,130) balance and unutilized COVID Vaccine doses are still available with the States/UTs and private hospitals to be administered.



National Commission for Women Urges Chief Secretaries To Take Measures To Close Gender Gap In Vaccination


Need To Create Public Health Awareness So That More And More Women Are Vaccinated On Priority: NCW Chairperson


‘Centre Has Been Running Intensified Vaccination Drives To Reach Every Nook & Cranny Of The Country’


The National Commission for Women, taking cognisance of a media report which highlights low uptake of COVID-19 jabs among women, has written to Chief Secretaries of all States/UTs urging them to take measures to close the gender gap in vaccination and to ensure that women are not left behind in the vaccination drive. The gap in immunisation coverage between the two genders is a matter of great concern for the Commission and therefore, Chairperson, Ms Rekha Sharma, in the letter, has mentioned that there is an urgent need to increase the proportion of women coming to vaccination booths for receiving the vaccine so that the gap in immunization coverage can be corrected.



First Nasal Vaccine Developed by Bharat Biotech supported by DBT-BIRAC gets nod of regulator for Phase 2/3 Trial


Bharat Biotech’s intranasal vaccine is the first nasal vaccine that has received the regulatory approval for Phase 2/3 trials. This is the first of its kind COVID-19 jab to undergo human clinical trials in India. BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.BBIL has in-licensed technology from Washington University in St Louis, USA.



Indian Immunologicals receive manufacturing license under Department of Biotechnology – Mission Covid Suraksha Project for Augmentation of Manufacturing Capacity for COVAXIN


Department of Biotechnology and BIRAC under the Mission Covid Suraksha announced by the Government of India, under Atmanirbhar Bharat 3.0 to accelerate the development and production of Indigenous COVID Vaccines, have lauched a project to augment production capacities of Covaxin.

Indian Immunologicals limited, Hyderabad, is the first site under this project to receive from CDSCO, a loan license for supplying Covaxin Drug Substance produced at its repurposed facility to Bharat Biotech. Indian Immunlogicals will supply the first lot of commercial Covaxin Drug Susbstance to Bharat Biotech on 13th August 2021. The facility will produce 2-3 million doses per month initially, and another 4-5 million doses from its new facility at Karkapatla, in next few weeks.



Chief Scientist, WHO Dr Soumya Swaminathan calls on Union Minister Dr Jitendra Singh and discusses various aspects of COVID pandemic


India has undertaken the fastest & the largest vaccination drive so far: Dr Jitendra Singh


Chief Scientist, WHO, Dr Soumya Swaminathan, yesterday called on Minister of State (Independent Charge) Science & Technology; Minister of State (Independent Charge) Earth Sciences; MoS PMO, Personnel, Public Grievances, Pensions, Atomic Energy and Space, Dr Jitendra Singh.Dr Soumya, who is an eminent medical professional and former Head of ICMR, discussed with Dr Jitendra Singh various aspects of the current COVID pandemic as well as a wide range of other issues.

Emphasising on the importance of mass vaccination through easy availability and accessibility, Dr Soumya said, even though the vaccine may not be able to provide absolute protection against different variants of Virus, it can certainly reduce the risk of death and complications. The Minister informed her that with the personal intervention and day-to-day personal monitoring by Prime Minister Narendra Modi, India has undertaken the fastest and the largest vaccination drive. On the call of Prime Minister Modi, people from all sections of the society are coming forward to cooperate.



Important Tweets




(Release ID: 1745545)
Visitor Counter : 9

Source link

Show More

Related Articles

Back to top button